ERBB2 and non-small cell lung carcinoma: The HER2-CD3-Fc bsAb significantly enhanced T cell cytotoxicity against the NSCLC cell lines A549 and NCI-H460 in a dose-dependent manner; furthermore, in the absence of T cells, the bsAb did not affect the tumor cells (Figure 2A,B).